Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $34.2 million.

  • CytomX Therapeutics' Cash & Equivalents fell 1575.07% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.2 million, marking a year-over-year decrease of 1575.07%. This contributed to the annual value of $38.1 million for FY2024, which is 12160.62% up from last year.
  • CytomX Therapeutics' Cash & Equivalents amounted to $34.2 million in Q3 2025, which was down 1575.07% from $49.0 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Cash & Equivalents ranged from a high of $329.7 million in Q1 2021 and a low of $17.2 million during Q4 2023
  • For the 5-year period, CytomX Therapeutics' Cash & Equivalents averaged around $108.2 million, with its median value being $56.4 million (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 13007.55% in 2021, then plummeted by 9113.3% in 2023.
  • Over the past 5 years, CytomX Therapeutics' Cash & Equivalents (Quarter) stood at $205.5 million in 2021, then fell by 5.78% to $193.6 million in 2022, then plummeted by 91.13% to $17.2 million in 2023, then soared by 121.61% to $38.1 million in 2024, then fell by 10.16% to $34.2 million in 2025.
  • Its last three reported values are $34.2 million in Q3 2025, $49.0 million for Q2 2025, and $47.6 million during Q1 2025.